ArticleRespiratory research2025
Risk of acute exacerbation of chronic obstructive pulmonary disease after COVID-19 recovery: a nationwide population-based cohort study.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Inflammatory bowel disease and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide retrospective cohort study in Korea.Journal of thoracic disease · 2026Article
- Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea.RMD open · 2026Article
- Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up.Journal of clinical medicine · 2026Review
- Long-term impact of SARS-CoV-2 on recurrent COPD exacerbations.EBioMedicine · 2026Article
- Article
- Effect of COVID-19 vaccination and SARS-CoV-2 infection status on mortality risk in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.Respiratory research · 2026Article
- Association between gastroesophageal reflux disease and incident bronchiectasis: a nationwide representative population-based study in Korea.BMC pulmonary medicine · 2025Article
- One-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study.BMJ open respiratory research · 2025Article
- Risk of Stroke in COVID-19 Survivors With Asthma: A Nationwide, Population-Based Cohort Study.Journal of Korean medical science · 2025Article
- Article
- Risk of pneumonia in individuals with rheumatoid arthritis: a nationwide cohort study.BMJ open respiratory research · 2025Article
- Incidence and risk factors for idiopathic pulmonary fibrosis in individuals aged 75 years and older in an ultra-aging society.Therapeutic advances in respiratory diseaseArticle
- Jing-Si Herbal Tea as a multitargeted complementary therapy: Evidence from preclinical and clinical studies.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is associated with severe Coronavirus disease 2019 (COVID-19) outcomes. However, it is uncertain whether the risk of acute exacerbation of COPD (AECOPD) increases after recovering from COVID-19.
methodsThis study included 2,118 individuals with COPD from the Korea National Health Insurance Service database who were also diagnosed with COVID-19. Matched controls were chosen using 1:1 propensity score (PS) matching. We compared the risk of AECOPD after COVID-19 recovery between the COVID-19 cohort and matched controls between October 8, 2020, and December 31, 2021, using PS-matched Cox proportional hazard regression models.
resultsDuring a median follow-up of 62 days (interquartile range, 29-179 days), including a median of 14 days of recovery time after COVID-19, 68 people (5.6%) in the COVID-19 cohort and 50 (3.9%) in the matched control group experienced AECOPD. Compared to the matched controls, the COVID-19 cohort had a significantly higher risk of overall AECOPD (hazard ratio [HR] = 1.45, 95% confidence interval [CI] = 1.09-1.92). This increased risk was particularly evident for severe AECOPD among individuals who had severe COVID-19 within the first 30days post-recovery (aHR = 8.14, 95% CI = 3.32-19.97). When classified by COVID-19 severity, while severe COVID-19 significantly increased this risk (aHR = 2.97, 95% CI = 2.15-4.11), non-severe COVID did not significantly influence the risk of AECOPD, regardless of time duration or exacerbation severity.
conclusionIndividuals with COPD who had severe COVID-19 have increased risk of AECOPD after COVID-19 recovery, especially within the first 30 days after COVID-19 recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.